51. Innovative diagnostic tools for early detection of Alzheimer's disease
- Author
-
Peter Garrard, Justin Dauwels, Yogesan Kanagasingam, Ralph N. Martins, Massimo Buscema, Stephanie A. Bridenbaugh, Stephan Mueller, Hamid R. Sohrabi, Shaun Frost, Sid E. O'Bryant, Surjo R. Soekadar, Karmele López-de-Ipiña, Christoph Linnemann, and Christoph Laske
- Subjects
medicine.medical_specialty ,etiology [Depression] ,Epidemiology ,physiology [Gait] ,Disease ,Eye ,methods [Diagnostic Tests, Routine] ,Cellular and Molecular Neuroscience ,blood [Alzheimer Disease] ,Developmental Neuroscience ,Neuroimaging ,Alzheimer Disease ,medicine ,Humans ,Dementia ,ddc:610 ,Neuropsychological assessment ,Intensive care medicine ,Psychiatry ,Gait ,Neurophysiological Monitoring ,Memory Disorders ,medicine.diagnostic_test ,Depression ,Diagnostic Tests, Routine ,business.industry ,Health Policy ,diagnosis [Alzheimer Disease] ,complications [Alzheimer Disease] ,Neuropsychological test ,medicine.disease ,etiology [Memory Disorders] ,3. Good health ,Electrophysiology ,Clinical trial ,Psychiatry and Mental health ,Early Diagnosis ,standards [Diagnostic Tests, Routine] ,Neurology (clinical) ,Geriatrics and Gerontology ,Alzheimer's disease ,physiopathology [Eye] ,business - Abstract
Current state-of-the-art diagnostic measures of Alzheimer's disease (AD) are invasive (cerebrospinal fluid analysis), expensive (neuroimaging) and time-consuming (neuropsychological assessment) and thus have limited accessibility as frontline screening and diagnostic tools for AD. Thus, there is an increasing need for additional noninvasive and/or cost-effective tools, allowing identification of subjects in the preclinical or early clinical stages of AD who could be suitable for further cognitive evaluation and dementia diagnostics. Implementation of such tests may facilitate early and potentially more effective therapeutic and preventative strategies for AD. Before applying them in clinical practice, these tools should be examined in ongoing large clinical trials. This review will summarize and highlight the most promising screening tools including neuropsychometric, clinical, blood, and neurophysiological tests.
- Published
- 2014
- Full Text
- View/download PDF